InvestorQ : Can I have your quick take on the quarterly results of Gland Pharma?
Archita Jajjoo made post

Can I have your quick take on the quarterly results of Gland Pharma?

Answer
image
Niti Shenoi answered.
12 months ago
Follow

The recently listed Hyderabad pharma company, Gland Pharma, saw Q3 PAT up 32.5% at Rs.204.11 crore on the strength of sales expansion. Sales did expand by 33.05% in the Dec-20 quarter to Rs.859.42 crore. This top line boost was driven by new product launches, geographical expansion and volume growth. It also filed 12 ANDAs with 6 ANDA approvals.

Operating profits for the Dec-20 quarter were up 27.6% at Rs.239 crore as revenues jumped much more than costs, despite supply chain disruptions. Despite that, due to a higher base, the OPM contracted from 29.03% in the Dec-19 quarter to 27.84% in Dec-20 quarter. During the same period, the PAT margins fell marginally from 23.86% to 23.75%.

There was growth across the board for Gland Pharma. India revenues were up 25% while revenues from rest of the world were up 3-fold on a smaller base. The largest markets of the US and Europe also grew 24%. Till date in FY21, Gland Pharma has filed 19 ANDAs, 5 DMFs and has secured a total of 24 ANDA approvals. Gland invested Rs.91.5 crore on R&D which is nearly 4% of sales.

0 Views